Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posoleucel for Virus-Associated Hemorrhagic Cystitis
NCT04390113Phase 3Terminated
- Sponsor
- AlloVir
- Start
- Mar 2021
- Primary completion
- Jan 2024
- Modality
- Native Immune Cells
- Countries
- 7
01
Overview
A Phase 3 trial of posoleucel in hemorrhagic cystitis (HC), BK virus infection, adenovirus infection, cytomegalovirus infection (CMV), Epstein-Barr virus infection, sponsored by AlloVir. Started Mar 2021; status: terminated.
02
Drugs
posoleucel
03
Conditions
hemorrhagic cystitis (HC)BK virus infectionadenovirus infectioncytomegalovirus infection (CMV)Epstein-Barr virus infection
Beyond the preview
Go deeper on NCT04390113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04390113.